148 related articles for article (PubMed ID: 28179321)
1. Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Woelich SK; Braun JT; Schoen MW; Ramlal R; Freter CE; Petruska PJ; Lionberger JM
Anticancer Res; 2017 Feb; 37(2):713-717. PubMed ID: 28179321
[TBL] [Abstract][Full Text] [Related]
2. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Shen Y; Chen J; Liu Y; Wu D
Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Seligson ND; Hobbs ALV; Leonard JM; Mills EL; Evans AG; Goorha S
Ann Pharmacother; 2018 May; 52(5):439-445. PubMed ID: 29241342
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
6. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
McHayleh W; Sehgal R; Redner RL; Raptis A; Agha M; Natale J; Luong TM; Schlesselman JJ; Foon KA; Boyiadzis M
Leuk Lymphoma; 2009 Nov; 50(11):1848-53. PubMed ID: 19860628
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Mayer K; Hahn-Ast C; Schwab K; Schmidt-Wolf IGH; Brossart P; Glasmacher A; von Lilienfeld-Toal M
Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Philpott N; Mehta J; Treleaven J; Powles R
Leuk Lymphoma; 1994 Sep; 15(1-2):127-30. PubMed ID: 7858489
[TBL] [Abstract][Full Text] [Related]
11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
12. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
13. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Juliusson G; Höglund M; Karlsson K; Löfgren C; Möllgård L; Paul C; Tidefelt U; Björkholm M;
Br J Haematol; 2003 Dec; 123(5):810-8. PubMed ID: 14632771
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
15. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
16. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Harousseau JL; Reiffers J; Hurteloup P; Milpied N; Guy H; Rigal-Huguet F; Facon T; Dufour P; Ifrah N
J Clin Oncol; 1989 Jan; 7(1):45-9. PubMed ID: 2642539
[TBL] [Abstract][Full Text] [Related]
18. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
[TBL] [Abstract][Full Text] [Related]
19. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
20. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Qasrawi A; Bahaj W; Qasrawi L; Abughanimeh O; Foxworth J; Gaur R
Ann Hematol; 2019 Mar; 98(3):561-579. PubMed ID: 30470874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]